Disrupting Drug Costs: The Role of Cost‐Plus Pricing in Reducing Medicare Spending on Hypertension Treatments
Adopting MCCPDC pricing could reduce Medicare costs for antihypertensive drugs, especially through 90-count supplies and first-line therapies. Targeted implementation-focusing on medications with clear cost and clinical advantages-may yield meaningful savings. These results support broader policy efforts to incorporate transparent, value-based drug pricing models into Medicare.
Authors
- Robert Witt (ORCID: https://orcid.org/0000-0003-0242-1434)
- Andrew V. Tran (ORCID: https://orcid.org/0000-0003-3855-1353)
- Jacob Duncan (ORCID: https://orcid.org/0000-0002-0990-0406)
- Annes Elfar (ORCID: https://orcid.org/0000-0002-4764-4503)
- Matt Vassar
- Matthew Rashid (ORCID: https://orcid.org/0000-0002-4194-0045)
Institutions
- Oklahoma State University Medical Center (US)
- Oklahoma State University Center for Health Sciences (US)
Publication Details
- Journal
- Health Services Research
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1111/1475-6773.70045
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00